rituximab,polatuzumab vedotin
roche
['dlbcl', 'lymphoma', 'lymsm', 'polarix']
#ash22 #lymsm pt ineligible for clinical trials based on lab criteria have inferior outcomes. more so in black pts. but is that because of the lab criteria themselves being adverse prognostic factors?? 
Clinician-researcher-educator bookworm @RoswellPark. Passionate about #Lymphoma #CLL #GeriOnc #PRO #MedEd Proud alum @OfficialJipmer @AIIMS_ND @UpstateNews